Status:
COMPLETED
Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy
Lead Sponsor:
University of Wuerzburg
Conditions:
Adrenal Tumor
Adrenocortical Carcinoma
Eligibility:
All Genders
30+ years
Phase:
PHASE1
PHASE2
Brief Summary
The improvement of conventional imaging techniques has led to an increased detection rate of different adrenal tumors. Since those tumors can belong to a variety of entities the therapeutic consequenc...
Eligibility Criteria
Inclusion
- Adrenal tumor seen by CT or MRT-scan with diameter of at least 2 cm or patient with adrenocortical carcinoma and suspected metastasis or local recurrence or patients with primary hyperaldosteronismus and adrenal tumour \> 1 cm
- Hormonal work up of of the adrenal tumor according to ENS@T (European network for the study of adrenal tumours)-criteria
- Age ≥ 30 Jahre
- Effective contraception (pearl index \<1%)
- Written informed consent
Exclusion
- Pregnancy or breast feeding
- Renal insufficiency (serum creatinine \> 2,0 mg/dl or MDRD \< 60 ml/min)
- Known allergy to etomidate or constituents of the test drug
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
End Date :
February 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00454103
Start Date
March 1 2007
End Date
February 1 2009
Last Update
August 18 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Würzburg, Germany, D-97080